SWX:GALDPharmaceuticals
Galderma (SWX:GALD) Valuation in Focus Following FDA Nod for Expanded Restylane Lyft Use
Galderma Group (SWX:GALD) received FDA approval for Restylane Lyft with Lidocaine, now cleared for chin augmentation in adults. Backed by pivotal trial data, this move further broadens Restylane Lyft’s indications in the US market.
See our latest analysis for Galderma Group.
Galderma Group’s FDA win added fresh momentum to its already impressive run this year. Recent gains have kept investor attention squarely on the company’s growth story. The stock’s 47.6% year-to-date share price return...